Anthropic’s IPO Pitch Faces Government Risk Amid Scrutiny
Anthropic aims to go public this fall, but mounting regulatory pressures risk undercutting its valuation. Investors a...
What Not To Do As A New Investor
Knowing what not to do as a new investor can save you time and money. Avoid common mistakes to build a successful investment portfolio.
28,184 articlesWhat Makes Bank Stock Worth Owning for Decades
If you’re looking for a steadier way to grow wealth over the long term, bank stock can be part of the answer. This gu...
Paul: Trump’s Policy ‘As Dangerous’ Sparks Market Debate Today
Ron Paul challenges President Trump’s move to hold government stakes in private companies, arguing it threatens liber...
Baidu Stock Drops Nearly 20% on $16.2B Impairment Shock
Baidu shares slumped after a hefty impairment charge underscored the heavy costs of its AI push, even as AI Cloud rev...
Say Thank Out: Strategist Urges Dump of Magnificent 7 Now
A top market strategist calls for exiting the Magnificent 7 amid lofty valuations and fading earnings promises, hinti...
Will Cerebras Soar After IPO? Lessons From History
As AI chips grab headlines, investors wonder if will cerebras soar after its IPO. While history offers clues, the pat...
What Best Gold 2026? Practical Ways to Own It Safely
Gold can play a role in a balanced portfolio, but the best approach in 2026 depends on your goals. This guide covers ...
Chris Olah? Atheist Anthropic Co-Founder at Vatican
A high-profile Vatican briefing on AI risk spotlights Chris Olah, the atheist Anthropic co-founder, urging external o...
Genghis Khan Worth $120: Markets Reframe Ancient Wealth
A widely cited estimate of Genghis Khan's wealth—genghis khan worth $120—sparks a timely discussion on how historians...
This Free Cash Flow ETF Quietly Surges in 2026 Amid Markets
A free cash flow ETF is delivering a surprising edge in 2026, outperforming the S&P 500 as investors rotate toward ca...
ISCB vs. SCHA: Which Small-Cap ETF to Buy in 2026?
Small-cap ETFs can boost growth, but choosing the right one matters. This guide breaks down ISCB and SCHA, showing ho...
XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status